This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

BELLUS Health Past Earnings Performance

Past criteria checks 0/6

BELLUS Health's earnings have been declining at an average annual rate of -44.7%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 41.4% per year.

Key information

-44.7%

Earnings growth rate

-24.4%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-41.4%
Return on equity-23.5%
Net Margin-578,586.7%
Last Earnings Update31 Mar 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BELLUS Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A4U Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 230-872169
31 Dec 220-761958
30 Sep 220-731953
30 Jun 220-711755
31 Mar 220-701558
31 Dec 210-711459
30 Sep 210-641352
30 Jun 210-471038
31 Mar 210-371029
31 Dec 200-321023
30 Sep 200-34925
30 Jun 200-351025
31 Mar 200-33823
31 Dec 190-26719
30 Sep 190-18514
30 Jun 190-14410
31 Mar 190-936
31 Dec 180-725
30 Sep 180-634
30 Jun 180-523
31 Mar 180-423
31 Dec 170-123
30 Sep 170-122
30 Jun 171021
31 Mar 171021
31 Dec 161-221
30 Sep 163-121
30 Jun 163021
31 Mar 163031
31 Dec 153021
30 Sep 152021
30 Jun 152-121
31 Mar 152-121
31 Dec 142-231
30 Sep 142-231
30 Jun 142-131
31 Mar 142-141
31 Dec 132-141
30 Sep 132-131
30 Jun 132-231
31 Mar 132-1031
31 Dec 122-1341
30 Sep 123-1551
30 Jun 123-1451

Quality Earnings: 0A4U is currently unprofitable.

Growing Profit Margin: 0A4U is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A4U is unprofitable, and losses have increased over the past 5 years at a rate of 44.7% per year.

Accelerating Growth: Unable to compare 0A4U's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0A4U is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7%).


Return on Equity

High ROE: 0A4U has a negative Return on Equity (-23.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/28 06:06
End of Day Share Price 2023/06/21 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BELLUS Health Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Justin ZelinBTIG
Pooya HemamiEdison Investment Research